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Abstract
Acquired epidermolysis bullosa is a rare subepidermal bullous disease character-
ized by autoantibodies to type VII collagen, the major component of anchoring fibrils. 
Although the exact pathophysiologic mechanism remains unclear, reduction or per-
turbation of the anchoring fibrils results subepidermal blister formation and clinical 
features such as skin fragility, blisters, erosions, scars, milia and nail loss. Acquired 
epidermolysis bullosa includes various clinical manifestations resembling genetic 
epidermolysis bullosa, bullous pemphigoid, cicatricial pemphigoid, Brunsting-Perry 
pemphigoid and linear immunoglobulin A bullous dermatosis. Numerous treatment 
options are available but patients are often refractory to treatment. Linear immuno-
globulin A bullous dermatosis is another subepidermal bullous disease characterized 
by the accumulation of IgA antibodies in lamina densa or sublamina densa region of 
the basement membrane and neutrophil-rich infiltrates in histopathology. It can be 
seen both in children and adults. The form seen in children usually begins under the 
age of 5 and it is called chronic bullous disease of childhood. The classical presenta-
tion is annular/polycyclic plaques and papules with blistering on perioral and perineal 
regions, giving a “cluster of jewels” appearance. The adult form is often seen after the 
fourth decade and clinical features are similar to those of dermatitis herpetiformis, bul-
lous pemphigoid or cicatricial pemphigoid.
Keywords: acquired epidermolysis bullosa, blisters, linear Ig A bullous dermatosis, 
subepidermal bullous diseases, linear IgA disease, chronic bullous dermatosis of 
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1. Acquired epidermolysis bullosa
1.1. Introduction
Acquired epidermolysis bullosa (AEB) is a chronic autoimmune subepidermal blistering 
disease characterized by autoantibodies to type VII collagen (C7), which is the main com-
ponent of anchoring fibrils (AFs) [1, 2]. AEB patients have both tissue bound and circulating 
immunoglobulin (Ig)G autoantibodies targeting C7 [3]. AFs participate in attachment of epi-
dermis and its underlying basement membrane zone (BMZ) to the dermis. It is thought that 
destruction of AFs due to autoantibodies targeting C7 results in a clinical phenotype of skin 
fragility, blisters, erosions, scars, milia and nail loss resembling genetic dystrophic epider-
molysis bullosa [4]. Pathogenicity of these anti-C7 IgG antibodies is proved by demonstrating 
AEB-like blistering disease development in immunocompetent mice when human AEB anti-
bodies were injected to them [5]. So, AEB results from an acquired autoimmune mechanism 
by which AFs can be compromised rather than by a gene defect as in hereditary dystrophic 
forms of epidermolysis bullosa (EB) [6].
AEB includes various clinical manifestations resembling dystrophic EB, bullous pemphigoid 
(BP), cicatricial pemphigoid (CP), Brunsting-Perry pemphigoid and linear immunoglobulin 
A bullous dermatosis (LABD) [7]. The diagnosis of AEB is often challenging because of these 
variety of clinical presentations. Evaluating patients only on the basis of clinical presentation 
and routine lesional histology is generally inadequate to distinguish AEB from other autoim-
mune subepidermal bullous diseases. Ancillary tests such as immunofluorescence, salt-split 
skin immunofluorescence (SSSI), transmission electron microscopy (TEM), immune electron 
microscopy (IEM), Western blot analysis, enzyme linked immunosorbent assay (ELISA) and 
fluorescent overlay antigen mapping (FOAM) are often necessary to confirm the diagnosis [8]. 
AEB is a chronic disease and often refractory to treatment but there have been developments 
in newer treatment modalities that have achieved some therapeutic success [9].
1.2. Historical aspects
AEB was initially described by G.T. Elliott in 1895 in two patients with acquired bullous dis-
ease reminiscent of EB who had no affected family members [10]. The term of “epidermolysis 
bullosa acquisita” was first coined by Kablitz in 1904 [11]. AEB was placed in the category 
of epidermolysis bullosa approximately 100 years ago because physicians were stuck by the 
similarity of clinical lesions seen in AEB patients and those seen in patients with hereditary 
dystrophic forms of EB [12]. In 1971, Roenigk et al. reviewed the AEB world literature and 
suggested the first diagnostic criteria for AEB: (1) spontaneous or trauma-induced blisters 
resembling hereditary dystrophic EB, (2) an adult onset of the disease, (3) a negative personal 
or family history for blistering disorder and (4) the exclusion of all other bullous diseases 
[13]. In 1980s, it was shown that patients with AEB had linear IgG deposits at their dermoepi-
dermal junction (DEJ) detected by direct immunofluorescence. By IEM, it was demonstrated 
that the IgG immune deposits in AEB were localized below the lamina densa differently 
from BP [3, 14]. After that, in 1984, Woodley et al. identified 290-kDa and 145-kDa proteins 
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as the target antigen of AEB using serum samples from nine patients as a source of antibod-
ies and concluded that AEB is a specific disease that is different from other primary bullous 
diseases [1]. This 290-kDa protein was later understood to be C7 [15]. A growing number of 
case reports about clinical presentations that are reminiscent of inflammatory BP, CP and 
Brunsting-Perry pemphigoid had reported in time [16–18].
1.3. Epidemiology and etiology
AEB is known as one of the rarest autoimmune blistering diseases with a incidence of approxi-
mately 0.17–0.5 per million people, per year and a prevalence of 2.84/million inhabitants [19–21]. 
The disease occurs at all ages but an epidemiological study of 30 Korean patients with AEB dem-
onstrated the average age of onset of disease to be 44 years [22]. Children can also be affected 
[23]. No gender predisposition is known [21, 22]. AEB was found significantly more frequent 
in black patients in France. In the same study, there was a significant human leucocyte anti-
gen (HLA)-DRB1*15:03 association with black patients from sub-Saharan Africa, suggesting a 
genetic predisposition to AEB in black patients of African origin [24].
The etiology of AEB is still unknown, but because the disease features IgG autoantibodies 
directed against C7, it is hypothesized that AEB may have an autoimmune pathogenesis 
[1, 2]. AEB is genetically associated with HLA-DR2; that is, HLA-DRB1*15 in black patients 
and HLA-DRB1*13 in Koreans [24–26]. HLA-DR2 phenotype has already been associated 
with hyperimmunity, which suggests an autoimmune etiology for AEB [25]. UV-radiation, 
vancomycin and contact allergy to metals have been reported as triggering factors of AEB in 
the literature [27, 28].
1.4. Pathophysiology
AEB is characterized by IgG autoantibodies directly attacking C7 within AFs [1, 2]. Although 
the precise role of autoantibodies against C7 in the pathogenesis of AEB is unclear, some clini-
cal evidences support pathogenic role of antibodies to C7 in AEB. Blister formation in neonate 
of an AEB mother suggests that autoantibodies transferring from mother play a pathogenic 
role in inducing neonatal AEB [29].
Exact pathopysiological mechanism is unclear but it is very likely that AFs are essential for 
adherence of the epidermal layer of skin to the dermal layer. Because, the patients who are 
born with a defect in the gene that encodes for C7 exhibit skin fragility and skin blisters just 
like AEB patients due to the paucity of normal AFs [30].
AFs are specialized attachment complexes localized to the epithelium-mesenchyme interface 
in several tissues. AFs extend from the lower portion of dermoepidermal basement mem-
brane to the underlying papillary dermis. They attach at both ends to the lamina densa, allow-
ing entrapment of interstitial collagen fibers into U-shaped structures [31]. Ultrastructural 
studies of AEB skin have demonstrated a paucity of AFs [3, 14].
C7 is composed of three identical polypeptide alpha chains, coiled around each other to form tri-
ple helix configuration. Each alpha chain has 145-kDa central collagenous domain, characterized 
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by repeating Gly-X-Y amino acid sequences and a 39-amino acid non collagenous hinge region. 
The central domain is flanked by a large 145-kDa amino-terminal noncollagenous domain (NC1) 
and a smaller 34-kDa carboxyl-terminal noncollagenous domain (NC2) [32].
The amino-terminal (NC1) domain is approximately 145 kDa in size and consists of submod-
ules with homology to adhesive proteins. NC1 includes a segment with homology to cartilage 
matrix protein (CMP), nine consecutive fibronectin type III-like repeats (FNIII), a segment 
with homology to the A domain of von Willebrand factor (VWF) and a short cysteine and 
proline-rich region [33, 34]. At the other end of the alpha chain, the carboxyl terminus, there is 
a much smaller non-collagenous globular domain called NC2, which is only 34 kDa [32]. The 
NC2 domain has a similar structure to the Kunitz protease inhibitor molecule [35].
Within the extracellular space, two C7 molecules align into antiparallel, tail-to-tail dimers. 
The carboxyl-terminal domains overlap between two C7 molecules, and the amino terminal 
domains present at the both ends of the molecule. Assembly of two C7 molecules is accom-
panied by proteolytic removal of a portion of the carboxy-terminal ends of both C7 molecules 
and stabilization by intermolecular disulfide bonding. Then, dimers aggregate laterally to 
form AFs, which are seen as semicircular loops in electron microscopy [36, 37].
NC1 interactions with several structural molecules of the BMZ such as type IV collagen, lam-
inin-332, fibronectin and type I dermal collagen were demonstrated using recombinant NC1 
expressed from human cells [35, 38, 39]. The seventh to ninth FNIII domains bind to lam-
inin-322 [38] and vWF domain binds to type 1 collagen [40]. The NC1 domain has been shown 
to be the major antigenic portion of C7 in AEB using epitope mapping [41, 42]. It is suggested 
that autoantibodies directed against NC1 compromise the function of these adhesive proteins 
and lead to epidermal-dermal disadherence [6].
The results of several studies indicated that the autoimmune response is the key element in 
the pathogenesis of AEB. Gammon et al. demonstrated that sera from AEB patients induced 
leukocyte recruitment to the DEJ using a leukocyte attachment assay [43]. Sitaru et al. showed 
that sera from AEB patients induced dermal-epidermal separation in the cryosections of nor-
mal human skin, whereas sera from healthy controls did not [44].
Besides in vivo studies, animal models for AEB were developed. In the first successful passive 
AEB model, the disease could be induced in mice by injection of autoantibodies against murine 
C7 derived from immune rabbits [45]. In the active disease model, the clinical, histopathological 
and immunopathological findings in AEB patients were reproduced in mice by immunization 
with a recombinant fragment of the murine NC1 domain [46]. The latter served to investigate 
the loss of tolerance to C7. Further studies showed that complement activation and infiltration 
of granulocytes into the skin are essential for AEB induction in animal models [47, 48].
A number of studies have provided direct evidence that human AEB autoantibodies to NC1 
domain of C7 are pathogenic and capable of inducing epidermal-dermal separation of skin. In 
one of them, affinity-purified anti-NC1 antibodies from AEB patients’ sera were injected into 
adult immunocompetent hairless mice. The mice developed subepidermal bullous disease 
reminiscent of human AEB [5]. Woodley et al. demonstrated a small N-terminal 227 amino 
acids CMP homology domain as the first antigenic epitope on C7 proven to be a pathogenic 
target for AEB by passive transfer of autoantibodies from patients [49].
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Subsequent evidences indicated the NC2 and the collagenous domains as to be minor targets for 
antibodies in AEB patients [50, 51]. Tissue-bound and circulating autoantibodies targeting the 
triple helical central domain of C7 were found in certain pediatric cases [52–54]. Minor antigenic 
epitopes localized to NC2 domain have also been demonstrated in recent reports [55]. AEB auto-
antibodies bound to NC2 domain may lead to epidermal-dermal disadherence by destabilizing 
AFs because of the role of NC2 and its adjacent collagenous segment in mediating antiparallel 
dimer formation of C7 [51]. As understood from these studies, AEB exhibits heterogeneous spec-
trum of autoantibody reactivities. But to date, there has been no evidence to indicate a correlation 
between epitope specificity of AEB autoantibodies and various clinicopathologic types [41, 56].
Analyses of the autoantibody response in AEB revealed the presence of IgG1 and IgG4 in the 
majority of patients [57, 58]. Complement-fixing IgG2a and IgG2b antibodies were detected in 
the basement membrane of AEB mouse models [46]. The Fc domains of IgG2a and IgG2b recruit 
neutrophils via Fc-gamma-RIV in the active mouse model. Inhibitor effect of Fc-gamma-RIIB 
and activator effect of Fc-gamma-RIV were demonstrated in the same study [59]. Complement 
factors are required for the blister formation in AEB, besides complement 5 (C5) knockout mice 
are resistant to blister development in a passive transfer mouse model [45]. T cells were proved 
to be required to produce blister-inducing antibodies in an active mouse model [60].
Development of inflammatory forms of AEB can be explained by the following sequential 
pathogenic scenarios: T cells stimulated by HLA-DR2 bearing antigen presenting cells that 
are presenting C7 subdomains. Activated T cells induce B cells and cause the produc-
tion of C7 antibodies. These antibodies bind to epitopes on the NC1 domain of C7. The 
Fc domains of the antibodies activate complements and recruit neutrophils. C5a induces 
FcRIIIA upregulation and FcRIIB downregulation on neutrophils. C7 antibodies bind 
to Fc receptors and provide neutrophil activation. Reactive oxygen radicals, serine and 
metalloproteases that are produced by neutrophils mediate extracellular protein proteoly-
sis. Blistering of mucocutaneous surfaces occurs as a consequence of the decrease in the 
amount of AFs [9, 35, 61, 62].
An experimental model for mechanobullous AEB has not been established yet so the 
pathomechanism of mechanobullous AEB is still unclear. But several possible mechanisms 
have been proposed [8]. It has been hypothesized that the normal interactions between NC1 
and its extracellular matrix ligands such as laminin 5, fibronectin and type 4 collagen inter-
rupted by autoantibodies may cause loss of the adherence of basement membrane and epi-
dermis onto the papillary dermis [38]. Another potential mechanism behind mechanobullous 
disease is that AEB autoantibodies may interfere directly with the antiparallel dimer forma-
tion of C7 and anchoring fibril assembly [51].
1.5. Clinical manifestations
Two major clinical types of AEB are recognized: mechanobullous and inflammatory [35]. 
However, AEB classically presents as a mechanobullous disease, if the disease is defined as 
autoimmunity to C7 AEB can have clinical presentations that are reminiscent of inflammatory 
BP, CP and Brunsting-Perry pemphigoid [63]. A rare presentation of AEB is characterized by 
IgA autoantibodies to C7 [64].
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There are five clinical presentations of AEB generally accepted: (1) classical presentation that 
is first reported and resembles the features seen in patients with inherited forms of DEB, (2) 
BP-like presentation, (3) CP-like presentation, (4) Brunsting-Perry pemphigoid–like presenta-
tion and (5) LABD-like disease [7, 63].
About two thirds of AEB patients present with one of the inflammatory variants. Some patients 
present with mixed phenotypes or in some, the clinical presentation may change during the 
course of the disease [65]. Kim et al. found no significant difference between mechanobullous 
and BP-like AEB with regard to sex, age of onset, oral involvement, treatment intensity or 
time to remission [22].
1.5.1. Classical AEB
This form is characterized by a mechanobullous disease with acral distribution [13]. Together 
with the BP-like AEB, classical AEB constitutes the majority of cases [22]. Milder forms of 
the disease are reminiscent of porphyria cutanea tarda, whereas its more severe forms are 
reminiscent of hereditary recessive dystrophic EB [14]. Patients present with skin fragility, 
trauma-induced blisters and erosions. Tense vesicles and bullae, which can be hemorrhagic, 
appear on non-inflamed or scarred skin [7]. Classical AEB is known to represent over trauma 
prone extensor surfaces such as back of the hands, knuckles, elbows, knees, sacral area and 
feet. Scaring reminiscent of hereditary dystrophic EB or porphyria cutanea tarda and pearl-
like milia cysts frequently occur by healing of blisters [66]. Crusts, scales, scarring alopecia, 
nail dystrophy and postinflammatory pigment changes are other secondary lesions which 
result from healing of blisters and erosions. Involvement of the oral mucosa is prominent with 
erosions and superficial blisters [12, 62].
1.5.2. BP-like presentation
Although AEB classically presents as a non-inflammatory mechanobullous disease, it may 
manifests as widespread vesiculobullous lesions on inflamed skin reminiscent of BP [16]. It 
is the most common type of inflammatory AEB [22]. BP-like AEB manifests as widespread 
pruritic erythematous vesicobullous eruptions that can occur in any mucocutaneous localiza-
tion [67]. The bullae are tense and localized on inflamed and/or urticarial skin of the trunk, 
extremities and skin folds [7]. In contrast to classical AEB, the distribution of the lesions is not 
confined to trauma-prone sites, skin fragility is not prominent and scarring and milia forma-
tion may be minimal or absent. Pruritus is frequent [8].
1.5.3. CP-like presentation
This form is characterized by a predominance of mucosal involvement and closely resemble 
CP [66]. Patients generally have erosions and scars of the mouth, upper esophagus, conjunc-
tiva, nose, anus and genitals with or without similar lesions on the glabrous skin [68–70]. 
It can lead to the same complications of CP, including synechia, ankyloblepharon, blind-
ness, nasal synechiae, laryngeal stenosis and dysphagia [71]. Tracheal involvement has also 
been reported [72]. Patients with the CP-like presentation often do not have trauma-induced 
lesions or skin fragility [35].
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1.5.4. Brunsting-Perry pemphigoid-like presentation
Brunsting-Perry pemphigoid-like AEB presents with clinical features of Brunsting-Perry CP 
but results from autoimmunity to C7 [73]. Patients have chronic, recurrent subepidermal 
blisters with atrophic scars confined to the head, neck and upper aspect of the trunk with 
minimal or no mucosal involvement [74, 75].
1.5.5. LABD-like presentation
LABD-like AEB has common features with LABD, including subepidermal bullous eruption, 
neutrophilic infiltration and linear IgA deposition on the BMZ [35]. Autoantibodies of these 
patients are usually identified as IgA, IgG or both [8]. Onset of the disease is usually after 
third decade but may be in childhood too. Erythematous urticarial plaques, vesicles, bullae, 
erythema multiforme-like lesions and skin erosions may be seen. Pruritus is significant but 
scars and milium cysts are rare. Mucosal involvement is seen in 30% of the cases [71]. Ig-A 
mediated AEB can be defined as immunobullous disease with IgA localized at the level of the 
(sub)lamina densa zone as witnessed by indirect IEM or direct IEM or by a dermal BMZ stain-
ing pattern on salt-split skin. So, it is sufficient to separate this disorder from classic LABD 
using these immunophenotypic criteria [64].
1.5.6. Childhood AEB
Generalized and inflammatory LABD-like skin lesions and mucosal involvement is frequent 
in this rare form [76]. Callot-Mellot et al. reviewed 14 children with AEB, 5 of the patients pre-
sented with a LABD-like disease and 5 patients presented with the BP-like form of AEB. The 
classical form of AEB was seen in 4 children [77]. Mayuzumi et al. reviewed 33 children with 
AEB and reported that the inflammatory phenotype, mucosal involvement and favorable 
prognosis were more common in children than adult AEB patients. Autoantibodies in child-
hood AEB often target more than one domain of C7 [78].
1.6. Diagnostic methods
Diagnosing AEB based on the clinical picture and skin standard pathology is not possible 
because of the variety of clinical presentations [71]. Direct immunogold electron micros-
copy has been considered the gold standard of diagnosis [14]. But at present, diagnosis 
can be made by serration pattern analysis of direct immunofluorescence (DIF) microcopy 
and/or detection of serum autoantibodies against type C7 [79]. Linear deposits of IgG, 
IgA and/or complement 3 (C3) along the DEJ with an u-serrated pattern are diagnostic for 
AEB. Several test systems for the serological diagnosis of AEB have recently become avail-
able. Sophisticated diagnostic approaches only available in specialized centers are required 
in some patients [63].
1.6.1. Histopathology
Histopathology of a lesional skin biopsy helps to distinguish subepidermal blistering diseases 
from intraepidermal disorders. Initial histologic changes in the lesional skin are papillary edema 
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and vacuolar alteration along the DEJ that are followed by subepidermal cleft and blister at a 
later stage [12]. In the classical mechanobullous form, minimal or no inflammatory infiltrate is 
detected in dermis. In the inflammatory subtypes of AEB, infiltration of neutrophils with vari-
able numbers of eosinophils, monocytes and lymphocytes are seen in the upper dermis [62, 80]. 
The infiltrate can be found around vessels, around follicles and in the interstitium. Fibrosis and 
milia formation are expected to be seen if cicatricial changes are present [12].
1.6.2. Transmission electron microscopy
Paucity of AFs and an amorphous, electron-dense band just beneath the lamina densa were 
demonstrated in the perilesional skin using electron microscopy [81] This finding could 
explain skin fragility by the similarity to that of EB hereditaria [82]. The cleavage plane of the 
blister does not indicate the diagnosis of AEB certainly. So, AEB cannot be differentiated from 
inherited epidermolysis bullosa and other pemphigoid disorders by TEM [63]. The cleavage 
may be seen either in the lamina lucida or the sublamina densa region [83]. Separation of 
the DEJ through the lamina lucida has been explained by the vulnerability of lamina lucida 
against proteolytic enzymes released during the inflammatory reaction at the BMZ [84]. The 
deeper level of separation in the classical form AEB may explain significant scar and milia 
formation, which is only rarely observed in the inflammatory type [85].
1.6.3. Immunoelectron microscopy
Direct IEM, which is approved as the diagnostic gold standard for AEB, allows to differenti-
ate AEB from other pemphigoid diseases by visualizing the deposits of autoantibodies in the 
sublamina densa [3, 8]. IEM detects IgG autoantibodies at the lamina densa and sublamina 
densa of the BMZ, whereas IgG autoantibodies are localized to the upper lamina lucida in BP 
[7]. Direct IEM is performed to determine the ultrastructural localization of in vivo-bound 
IgG autoantibodies at the BMZ. Indirect IEM shows the binding site of circulating IgG autoan-
tibodies at the BMZ [85]. Direct IEM is a sensitive diagnostic method, but it is a sophisticated 
procedure only available in few centers for the diagnosis of AEB [63].
1.6.4. Direct immunofluorescence
Immunofluorescence techniques maintain the pivotal role in the diagnostic algorithm of 
AEB. DIF on perilesional skin (with a radius of 1 cm) demonstrates linear binding of IgG and/
or IgA, and/or C3 deposits along the dermal-epidermal junction [14, 63]. The deposition of 
multiple conjugates, including IgG, IgA, IgM, C3, complement 4 (C4) and properdin, is more 
frequently in AEB [85]. In LABD-like presentation, linear Ig A deposition presents without 
IgG [86].
BP has clinical and histopathological features, which may often be confused with AEB. DIF 
typically demonstrate linear deposition of IgG and C3 in the BMZ in both conditions [87]. 
Thus, salt split technique (SST) was introduced in 1984 to differentiate pemphigoid group 
from other subepidermal bullous diseases [88]. If skin samples are incubated in 1 M NaCl 
at 4°C for 24–72 hours, the epidermis can be pulled away from dermis with a fine forceps 
[6, 87–89].
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Direct salt-split skin immunofluorescence can be used to distinguish AEB from BP. A routine 
DIF is performed on perilesional skin from patients who is fractured at the DEJ, through 
the lamina lucida zone. This cleavage places BP antigen on the epidermal side of the split, 
and other BMZ components including C7 on the dermal side. Therefore, if fluorescent label 
is observed along epidermal side of the salt-split skin, AEB is effectively excluded and the 
diagnosis of BP is suggested [8, 14]. But, this method is not sufficient to confirm AEB because 
anti-p200, protein-105 pemphigoid (Chan’s disease) and anti-laminin-322 CP also show posi-
tive staining on the dermal side of the salt-split skin [7, 90–92].
Vodegel et al. demonstrated that IgG/IgA deposits at the BMZ can ultrastructurally be seen as 
upstanding arms between the rootlets of the basal keratinocytes, thus making u shapes [79]. 
U-serrated immunodeposition pattern in DIF is pathognomonic feature for AEB and bullous 
systemic lupus erythematosus (SLE), which are characterized with autoantibodies against 
C7 [65, 93]. Bullous SLE can be ruled out by other serologic and clinical criteria [7]. All other 
pemphigoid diseases show true linear or n-serrated pattern [93–95]. These patterns can be 
applied by DIF only. However, serration pattern may not be identified in mucosal biopsies 
and a number of skin samples [63, 96].
1.6.5. Indirect immunofluorescence (IIF)
IIF microscopy can be applied for detecting circulating antibodies. Standard substrates for 
this technique are monkey or rabbit esophagus as well as normal human skin. Incubation 
with 1 M NaCl solution of these substrates leads to cleavage within the lamina lucida [89]. 
So, IIF can also be done in salt-split skin with increased sensitivity [63]. Salt-split IIF allows to 
differentiate AEB from BP and LABD. Because AEB sera react on the dermal side (floor of the 
blister) of the salt-split skin, whereas BP and LABD sera react on the epidermal side (roof of 
the blister) [96]. A positive IIF result on the dermal side of the cleft does not make the diag-
nosis of AEB certain because dermal staining is also observed in patients with bullous SLE, 
anti-p200 pemphigoid, anti-epiligrin (laminin-332) CP and Chan’s disease [7, 73, 90, 92, 97].
Another diagnostic method is IIF using substrate deficient in basement membrane molecules. 
C7-deficient skin from patients with dystrophic EB is required to perform this test. AEB sera 
does not show any labeling of skin deficient in C7, but linear fluorescence is seen at the BMZ 
on normal/salt-split human skin as well as on laminin-332–deficient skin [18, 73].
1.6.6. Western immunoblotting
Immunoblotting analyses are effective to confirm the diagnosis of AEB [8]. Dermal extracts 
from skin, amnion or cell culture are subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and electrophoretically transferred to a nitrocellulose membrane 
[12]. Recombinant forms of C7 can also be used [8]. When the membranes with immobilized 
proteins are incubated with AEB and control sera, AEB sera will be visualized by binding to 
a 290-kDa band, the alpha chain of C7, whereas control sera will not [8]. A second band of 
145 kDa, which corresponds to NC1 domain of C7, will also be labeled with AEB antibodies 
[12]. Anti p-200 pemphigoid and AEB can be differentiated by Western blot. Patients’ sera 
react with 200- and 290-kDa proteins in anti p-200 pemphigoid and AEB, respectively [62]. 
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Although the sensitivity of immunoblotting is approximately 60%, using several recombi-
nant proteins covering four immunodominant epitopes of NC1 domain increases to 80% [42].
1.6.7. Serology
Enzyme-linked immunosorbent assay (ELISA) demonstrates the presence of patient’s circu-
lating autoantibodies against specific basement membrane antigens [8]. AEB ELISAs have 
been developed using recombinant domains of C7, starting from the NC1 domain [35, 98]. 
The sensitivity and specificity of an ELISA system using NC1 domain were 94.5% and 98.7%, 
respectively, in the study of Komorowski et al. [99]. Recombinant NC1 and NC2 domains of 
C7 were also used in an ELISA system for AEB with sensitivity of 93.8% and specificity of 
98.1% [100]. Autoantibodies to NC2 domain were detected in 20% of AEB patients by ELISA 
[71]. A positive correlation between ELISA values and disease severity of AEB patients was 
found in several studies [22, 101]. Compared to Western blotting and electron microscopy, 
ELISA is faster and easier to perform. ELISA method is also more sensitive because it detects 
autoantibodies that recognize the tertiary and quaternary structure of an antigen, whereas 
Western blotting only detects antibodies binding denatured, reduced proteins [8].
1.6.8. Fluorescence overlay antigen mapping
It is an efficient technique for identifying localization BMZ components and pathogenic anti-
bodies on perilesional skin from patients with autoimmune diseases [8]. The skin samples 
are subjected to co-incubation with monoclonal antibodies against human IgG and type VII 
collagen separately and then stained with different fluorescent stains. Computer-aided super-
position of the fluorescent-stained images allows to detect IgG deposits, which can be above 
(BP) or at the same location of C7 (AEB) [102].
1.7. Diagnosis
In a patient with clinical picture compatible with AEB, the initial and the gold standard diag-
nostic test is DIF microscopy including serration pattern analyses (u-serrated: AEB, n-ser-
rated: other subepidermal diseases). When IgG/IgA/C3 along the DEJ is observed without a 
serration pattern, IIF microscopy on human salt-split is the next diagnostic procedure. IgA/
IgG at the epidermal side refers to the diagnosis of BP, CP or LABD.
If IIF microscopy is negative or IgA/IgG at the dermal side of the split is detected, then 
C7-specific ELISA or IIF (Euroimmun, MBL) should be performed (even when diagnosis of 
AEB has been established by pattern analysis of DIF or direct IEM, serum should be ana-
lyzed for autoantibodies against C7). Immunoblotting, IIF microscopy on C7 deficient skin, 
FOAM and direct IEM are the next diagnostic tools (depending on availability), in case of 
negative ELISA result. Positivity in any of the four assays will allow diagnosis of AEB [63].
1.8. Differential diagnosis
BP is characterized by predominant IgG reactivity by DIF and/or IIF microscopy, no floor 
binding by IIF microscopy and no predominant mucosal involvement. CP presents with 
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predominant mucosal involvement. When floor binding is detected by IIF microscopy, lam-
inin-332 reactivity needs to be analyzed. LABD shows predominant IgA reactivity by DIF 
and/or IIF microscopy. Anti-p200 pemphigoid is characterized by reactivity with the p-200 
protein and/or laminin γ1 [63].
1.9. The relationship between AEB and other systemic diseases
A variety of other diseases were reported to be coexisting with AEB [12]. Inflammatory bowel 
diseases, especially Crohn’s disease, is the most common disorder associated with AEB [103]. 
While in the United States, 25% of AEB patients also have inflammatory bowel disease; this 
association is not found in Korean patients [22, 104]. Rheumatoid arthritis, diabetes, cryo-
globulinemia, psoriasis and hematological malignancies were also reported to be associated 
with AEB in anecdotal reports [105–107].
1.10. Treatment
Management of AEB is challenging, because noninflammatory mechanobullous form is often 
refractory to treatment, and the inflammatory forms may require the use of high-dose cortico-
steroids combined with other immunosuppressants resulting in increased morbidity [62]. All 
patients need supportive therapy to help reduce risk of complications of AEB. Education for 
avoiding trauma and wound management improve their quality of life [12]. The most widely 
used medication for treatment of AEB is systemic corticosteroids but the outcome is usually 
poor. Mild clinical features respond well to low-dose (05–1 mg/kg/day) corticosteroid therapy, 
whereas high-dose (1–1.5 mg/kg/day) corticosteroid therapy is mandatory in some patients [62].
Colchicine (2 mg/day) has been reported to be effective in patients with both classical and 
inflammatory presentations probably by the mechanism of inhibiting antigen presentation to 
T cells [108]. The side effect profile of colchicine is relatively benign so it is often used as a first-
line drug alone or combined with corticosteroids [62]. Dapson (25–100 mg/day) is also effec-
tive in some patients, especially when neutrophils are present in their dermal infiltration [109].
Because of the unsatisfactory outcome and extensive side effects of systemic corticosteroids, 
immunosuppressive agents are required as adjuvant regimens [62]. Although a number of 
patients have been reported to respond to cyclosporine therapy (>6 mg/kg/day), the use of 
cyclosporine is limited due to the long-term toxicity of the drug [110]. In intractable cases, 
it is recommended to use cyclosporine (3–60 mg/kg/day) in addition to corticosteroids [62].
Mycophenolate mofetil (1–2 g/day), methotrexate (7.5 mg/week), and pulse cyclophospha-
mide (500 mg for 1 day) can be used for their steroid-sparing effects in patients with inflam-
matory forms. The effectiveness of these agents is varied among patients [62].
Intravenous immunoglobulin G (IVIG) has been used successfully in some severe refractory 
AEB patients. IVIG has the advantage of lacking immunosuppression [111]. It is recommended 
for patients not responding to conventional therapy [62]. Rituximab decreases the number of 
circulating B cells, plasma cells and amount of antibody production. It was used successfully 
in a small number of severe and refractory patients [35, 112]. Plasmapheresis, immunoadsorp-
tion and photopheresis are other therapeutic modalities; however, the experience of using 
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them in AEB is fairly limited [8, 35]. Infliximab is considered to be an alternative treatment 
of patients with AEB in future [35]. In a study conducted by Le Roux-Villet et al., 206 articles 
were analyzed; it was emphasized that only two were of an adequate level of proof, with four 
of intermediate level and all the others of only low level. Therefore, it is difficult to suggest 
optimal treatment. Further data are needed to establish the optimal treatment approach [113].
2. Linear immunoglobulin A bullous dermatosis
2.1. Introduction
LABD, also known as Linear IgA disease, is a rare autoimmune subepidermal bullous disease 
affecting adults and children, which is characterized by the linear deposits of IgA antibodies 
in BMZ [114, 115]. LABD is usually idiopathic, but medications, malignancies and infections 
may play a role in the etiology of LABD. The primary implicated agent is vancomycin [116]. 
In the adult-onset form, arcuate or linear tense vesicles and bullae arising on urticarial looking 
plaques or normal skin localize on the extensor surfaces [115]. Childhood-onset LABD, which 
is historically known as chronic bullous dermatosis of childhood (CBDC), represents the most 
common autoimmune bullous disease among children [117]. The childhood-onset form of 
LABD has a slightly different presentation with perioral, periorbital, genital and lower limb 
localization. Annular polycyclic “string-of-pearls” sign is more common in the childhood 
form [115]. Target antigens of circulating antibodies exhibit heterogeneous features as well as 
the clinical presentations. LABD is immune serologically divided into two subgroups accord-
ing to the reaction with the epidermal/dermal sides of 1 mol L NaCl-split normal human skin 
in IIF [118]. In the lamina lucida-type LABD, the major target antigens are the 120-kDa LAD-1 
antigen and its carboxyterminal proteolysed form 97-kDa LABD97 antigen. In the sublamina 
densa-type LABD, the splitting level is deeper and the target antigen is C7 [117, 119]. Other 
certain incriminated antigens are BP230, BP180 NC16a domain, 285-kDa antigen, laminin-332 
and 200-kDa laminin γ1 [120]. Autoimmune diseases (post-streptococcal glomerulonephri-
tis), inflammatory bowel disease (ulcerative colitis) and lymphoproliferative disorders were 
reported to trigger LABD with an unknown mechanism [121]. Skin lesions respond rapidly to 
dapsone or sulfapyridine treatment [122].
2.2. Historical aspect
LABD was firstly described in children with nonpruritic mucocutaneous blisters misdiag-
nosed as dermatitis herpetiformis (DH) [123]. Subsequent patients were called “bullous pem-
phigoid of childhood,” “childhood DH” and finally “chronic bullous dermatosis of childhood” 
by other clinicians [124]. After that, continuous linear deposits of IgA along the BMZ were 
showed [125]. Currently, it is known as the childhood counterpart of LABD [114].
2.3. Epidemiology
Reported incidence rates were 0.23/million/year in Germany [126], 0.49/million/year in France 
[19] and 2.3/million/year in Kuwait [127]. Interestingly, LABD was reported to be more frequent 
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in Uganda [128], South Africa [129], Mali [130] and Tunus [131]. This may be explained with the 
variation of age distribution in these countries compared to others. No racial or gender predi-
lection has been reported [132]. LABD can affect all ages, but two peaks have been frequently 
observed: childhood onset and adult onset [133]. The childhood-onset form usually appears 
between 6 months and 5–6 years of age. Spontaneous remission may occur within 5 years or it 
may persist until puberty. On the other hand, the adult-onset form generally appears after the 
sixth decade and tends to be more chronic [114, 117]. Neonatal cases are extremely rare [134].
2.4. Etiology
Several studies were carried out to assess the possible effect of genetic predisposition for 
LABD. Collier et al. showed an increased frequency of HLA Cw7, B8, DR3, DQ2 and tumor 
necrosis factor (TNF2) alleles. Genetic association of HLA-Cw7, HLA-B8 and HLA-DR3 with 
LABD was reported especially in childhood form rather than the adult form. TNF2 allele was 
associated with worse prognosis in both children and adult groups [135]. HLA-B8 haplotype 
was found to be related with favorable prognosis [136].
Although LABD is mostly idiopathic, there are several precipitating factors, such as drugs, infec-
tions and malignancies, and traumatic events, such as burns and ultraviolet light exposure [114, 
117]. Intake of certain drugs, most commonly vancomycin [137], has been implicated as the causal 
agent. In addition to this, over 20 other medications have been suspected as potential triggers in 
case reports [138–142]. (Table 1) Drug-related cases are responsible from 37.5% of adult patients 
[115]. It is possible that these drugs cross-react with autoantigens of the BMZ by changing their 
conformational structure or unmasking previously hidden antigens to the immune system [143].
Antimicrobials Ace inhibitors/angiotensin receptor blockers Antiepileptics
Vancomycin Captopril Phenytoin
Penicillin Eprosartan Carbamazepine
Cephalosporins Candesartan Vigabatrin
Sulfonamide Antiarrhythmics Antidiabetics
Piperacillin-tazobactam Amiodarone Glibenclamide
Rifampin Verapamil Glyburide
Imipenem Immunomodulating agents Miscellaneous drugs
Nonsteroidal anti-inflammatory 
drugs
Cyclosporine Atorvastatin
Diclofenac Ustekinumab Furosemide
Naproxen Infliximab Lithium carbonate
Piroxicam Granulocyte colony-stimulating factor Somatostatin
Ketoprofen Interferon-α,γ Gemcitabine
Oxaprozin Interleukin-2
Table 1. Medications associated with drug-induced LABD.
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LABD has been associated with lymphoproliferative malignancies, especially non- Hodgkin 
lymphoma and Hodgkin lymphoma [144]. Besides, association with solid organ malig-
nancies has also been reported, including bladder, esophagus, breast, uterus, colon and 
thyroid carcinoma [145–147]. There are documented two LABD cases, which occur after 
influenza and human papillomavirus vaccination [148]. Additionally, LABD is triggered by 
upper respiratory infections, varicella zoster virus and antibiotic-treated tetanus infections. 
Perhaps infectious agents may play a role in the development of autoimmune response 
[149, 150].
Inflammatory bowel diseases, mainly ulcerative colitis, are the most common diseases 
associated with LABD. The chronic inflammation in the gastrointestinal tract is thought 
to be responsible in abnormal IgA production. The cross-reaction of colonic epithelial cells 
and cutaneous BMZ antigens may be related to this coexistence [151]. Although a definite 
association is yet to be established, LABD has also been reported with primary amyloidosis 
[152], interstitial pneumonia [153], rheumatoid arthritis [154], SLE [155] and glomerulone-
phritis (Table 2) [156].
2.5. Pathogenesis
Linear IgA disease is a subepidermal immunobullous disease characterized by IgA auto-
antibodies directed against several antigens located in the BMZ of the skin and mucosal 
tissues lined with stratified squamous epithelia. Despite many studies over several decades, 
the pathophysiologic mechanism that triggers the autoimmune response in LABD still 
Lymphoproliferative malignancies
Non-Hodgkin lymphoma
Hodgkin lymphoma
Solid organ malignancies
Bladder, esophagus, breast, uterus, colon and thyroid carcinoma
Inflammatory bowel diseases
Ulcerative colitis
Crohn’s disease
Primary amyloidosis
Interstitial pneumonia
Rheumatoid arthritis
SLE
Glomerulonephritis
Table 2. Disorders associated with LABD.
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needs to be better clarified [114]. Target antigens of circulating autoantibodies are classi-
fied into two groups, those residing in lamina lucida and those in sublamina densa. From 
this point of view, LABD is divided into two subgroups, lamina lucida-type and sublamina 
densa-type [157, 158].
Using 1 mol L NaCl-split normal human skin as a substrate for IIF, the majority of the patients’ 
sera shows epidermal binding, which implies an antigen associated with hemidesmosomes 
or the upper lamina lucida, and a minority of those bind to the dermal aspect of the artificial 
blister suggests a lower lamina lucida or dermal antigen. However, some patients’ sera show 
reactivity to both epidermal and dermal sides (mixed type) [159]. In patients with lamina 
lucida-type LABD, IgA autoantibodies react most frequently with the 97-kDa protein (LABD-
97) and 120-kDa protein (LAD-1) [160, 161]. These two most common LABD antigens are 
fragments of BP180 ectodomain [162, 163].
BP180, or collagen XVII, is a transmembrane hemidesmosome-associated protein with an 
extracellular collagenous domain spanning the lamina lucida [164]. The extracellular domain 
of BP180/collagen XVII molecule is partly shed and is further fragmented by proteolytic 
action into neoepitopes [162]. The LAD-1 is generated when collagen XVII is cleaved by kera-
tinocyte metalloproteinases, ADAM-9 and 10 [165]. This cleavage is just in the noncollag-
enous (NC)16A domain of the BP180, and this explains that 20% of the sera of LABD patients 
react with the NC16A domain [117, 166]. NC16A domain, which is the major pathogenic epi-
tope in the extracellular domain of BP180 in BP, is also a target for IgA antibodies in LABD, 
frequently in conjunction with other antigenic targets [167]. LABD97 is cleaved from NC16 
domain of collagen XVII as well as LAD1, and further C-terminal processing of LAD1 induces 
LABD-97 [168, 169]. IgA antibodies to 290-kDa antigen (C7) and 255-kDa dermal antigen are 
most frequently detected in patients with sublamina densa-type LABD [170, 171]. Tsuchisaka 
et al. demonstrated that C7 is the major autoantigen for sublamina densa-type LABD [119]. A 
285-kDa antigen (LAD285) has been found in patients whose sera have both dermal and epi-
dermal binding on immunofluorescence testing using split skin [172, 173]. LAD285 is thought 
to be the immunodominant dermal-associated antigen, which represent the site of the original 
antibody attack in patients with a response to dermal and epidermal antigens [173]. The full-
length BP180, BP230, laminin-332, laminin γ1 and α6β4 integrin are less common antigenic 
targets of IgA [174–176].
Most of the patients’ sera have more than 1 target antigen suggesting that there is a primary 
disease-provoking epitope with spread of the immune response to other epitopes on the same 
or adjacent molecules. It is also demonstrated that the phenomenon of intermolecular epitope 
spreading is common, age dependent in LABD and is associated with IgA antibodies rather 
than IgG antibodies [173].
The pathogenesis involves IgA and less frequently IgG autoantibodies directed against BMZ 
antigens [172]. Previous investigations have demonstrated that A1 subclass is responsible 
for development of the disease [177]. IgA is a chemoattractant of neutrophilic granulo-
cytes. Antigen-antibody binding leads to complement activation, predominantly neutro-
philic inflammatory infiltration and proteolysis mainly occurs through the  cooperation of 
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 neutrophil elastase and MMP-9/gelatinase B that result in tissue injury and blister formation 
[114, 142, 178, 179]. There is indirect evidence for the pathogenicity of the IgA antibodies. 
A recent research has demonstrated that transfer of monoclonal IgA antibodies against the 
97-kDa LAD antigen into severe combined immunodeficient mice with human skin grafts 
resulted in IgA deposits along the BMZ, recruitment of neutrophils, and subepidermal ves-
icle formation [180].
2.6. Clinical features
Clinical manifestations of LABD are heterogenous and often resemble those of BP and 
DH. Characteristic clinical features are tense vesicles and/or bullae on the normal/erythema-
tous/urticarial base [181].
These lesions may occur in various size and form as annular or polycystic plaques. As referred 
before, there are two forms of LABD: adult onset and childhood onset (CBDC). The distribu-
tion of the lesions differs in these two forms.
Lesions in CBDC mostly occur in the lower abdomen and anogenital areas, with a fre-
quent involvement of the perineum and less often perioral area. New lesions appear in 
the periphery of older ones, named as “cluster of jewels.” The localization in the lower 
 abdomen and the anogenital region is typical for childhood form. Patients complain of 
severe itching and burning and rupture of blisters may develop secondary infections 
[114, 182].
In adults, there may be several clinical manifestations such as papular, vesicular, bullous, 
erythematous and edematous lesions that localized on extensor surfaces, including trunk 
and buttocks. Erythema multiforme-like, prurigo nodularis-like [183] and contact dermati-
tis-like lesions [184] may occur. These lesions may distribute symmetrically or asymmetri-
cally in both child and adult forms. It is difficult to distinguish disease from DH especially 
in the presence of symmetrical excoriated pruritic papules. LABD should be considered 
when the annular lesions are present. Larger bullae can be seen in some patients with BP or 
AEB. Histopathological and serological examinations should be performed to differentiate 
LABD from all these diseases [181, 185].
Oral mucosa and ocular surface are the most common locations in LABD [186]. Larynx, 
pharynx, trachea, esophagus and vaginal mucosa may be affected. The involvement of oral 
mucosa occurs in 60–70% of LABD patients. It is more common in adults. These mucosal 
lesions may be the only clinical manifestation in truly minority of patients. Painful erosions 
or ulcers or desquamative gingivitis may occur in oral mucosa [187, 188]. Ocular lesions heal 
with scar just like CP. Ocular findings include dry eye, foreign body sensation, entropion, 
conjunctival scarring with trichiasis, corneal opacification, neovascularization and potential 
blindness [189].
Recent case series demonstrated that the course of drug-induced LABD is atypical and 
more severe compared to the idiopathic form. Lesions usually occur within 5 to 26 days 
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(median 10 days) after drug intake and usually resolve within 4 weeks after drug with-
drawal. But exceptional cases may persist for months. Vancomycin is the most commonly 
prescribed drug. Drug-induced LABD may clinically resemble toxic epidermal necroly-
sis with large erosions and positive Nikolsky sign [190, 191]. Morbilliform and localized 
palmar variants have been defined and the responsible drug in these variants is usually 
vancomycin [192, 193].
2.7. Diagnosis
The diagnosis of LABD is based on clinical, histopathologic and immunologic parameters 
[114]. Routine histopathology of the lesional skin classically shows subepithelial blister 
formation with a diffuse underlying neutrophilic infiltrate in the dermis accompanying 
mononuclear cells and eosinophils. These findings are identical to those of DH [194]. But 
neutrophils are usually much less diffuse and are more common in papillary tips in DH 
[116]. These findings can be observed in other subepidermal blistering diseases such as BP 
and AEB [195].
Owing to the fact that clinical and histologic features of LABD are frequently overlap with 
those of other subepidermal bullous diseases, it is essential to verify the presence of IgA 
autoantibodies using at least one of the immunopathologic examinations, including DIF, 
IIF, Western immunoblotting or IEM [114]. The gold standard test for diagnosis of LABD is 
DIF microscopy of perilesional, clinically normal-appearing skin or mucous membrane that 
reveals linear IgA deposits along the BMZ [196]. The forearm is not a suitable biopsy site, 
as antigen expression is detected to be insufficient [197]. In cases of lamina lucida-type of 
LAD, immunofluorescence analysis of perilesional skin biopsies show linear Ig A deposits 
that have n-serrated pattern in contrast to sublamina densa-type LAD where the deposits 
have an u-serrated pattern [117]. Deposition of IgG, IgM, or C3 in conjunction with IgA may 
be seen in some cases [114]. The presence of linear IgG deposition in addition to IgA along 
the BMZ has provoked some controversy [116]. In some cases of DH, the pattern of the IgA 
deposition may be linear. So, it might be necessary to use another confirmatory immunologic 
test for distinguishing DH from LABD [198].
Serum and, rarely, blister fluid are used for IIF to detect circulating IgA antibodies [199]. 
IIF shows a variable positivity of 30–50% of LABD patients and tends to be more positive in 
children (≥75%) than in adults (30%) [133, 182, 200]. As the low circulating autoantibody titers 
make difficult to detect positivity, it should be done on salt-split human skin for increased 
sensitivity [201]. IgA deposits can be detected on epidermal, dermal or both sides of the salt-
split skin by IIF. In most cases, sera of the patients show epidermal bindings (lamina lucida-
type LABD) [159]. Sublamina densa-type LAD accounts for the minority of the patients and 
shows dermal binding [202]. Some cases show a mixed pattern [203]. IIF on salt-split skin is 
usually negative in drug-induced LABD [191].
IEM is a specific diagnostic tool, which detects the exact location of immune deposits but it is 
expensive and only used by small numbers of centers [114]. By direct IEM, the IgA deposits 
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were found in lamina lucida, basal surface of hemidesmosomes, lamina densa and sublamina 
densa region [204]. “Mirror image” is defined as the IEM finding of several cases in which the 
immune deposits are located at the both sides of lamina densa [205].
Western blot is not commonly used because it is time-consuming, expensive and not feasible 
in most centers [116]. But multiple target antigens have been identified by the Western blot 
analysis within last 20 years [114]. It is a sensitive method for detecting IgA antibodies against 
LABD97 and LAD-1 [117, 172]. Remaining recognized antigens, including BP180, BP230 and 
C7 that are shared by other subepidermal bullous diseases, make the diagnosis more chal-
lenging [114]. When the mentioned methods do not provide information, Western blot analy-
sis can enable to reach an accurate diagnosis [206].
2.8. Differential diagnosis
Clinically, LABD can resemble other blistering disorders such as BP, DH, AEB, CP and bul-
lous SLE [114]. BP is characterized by linear deposition in the BMZ of IgG and C3 while 
immunofluorescence studies for DH demonstrate granular IgA deposits in the dermal papil-
lae [207]. Cases reported to show IgA autoantibodies to the 290-kDa C7 may be diagnosed as 
sublamina densa-type LABD or IgA-mediated AEB. However, other clinical characteristics, 
such as milia and atrophic scarring, can be used to differentiate AEB from LABD [208]. LABD 
with predominant mucosal involvement can mimic CP clinically, but differentiates by immu-
nofluorescence findings from other bullous diseases.
Salt split-skin immunofluorescence assays demonstrate that both circulating and tissue-fixed 
IgA autoantibodies mostly deposit on the roof of the split in LABD. In CP, antibodies are seen 
on the floor or roof of the split [209]. AEB is always recognized by dermal deposits. In LABD 
patients’ sera, autoantibodies are mainly against 97- or 120-kDa antigens, whereas autoanti-
bodies in BP patients target 180 and/or 230 kDa antigens [210]. Circulating and tissue-bound 
antibodies target 180-kDa or laminin-322 in CP patients [209] and 145- or 290-kDa antigens in 
AEB patients [64].
Although several authors have suggested their own criteria, there is no diagnostic guideline 
or consensus about LABD [116]. Some investigators suggest that solely linear IgA deposition 
with no other immunoglobulins or complement deposition at the BMZ in DIF is essential 
[202]. However, others proposed that prominent linear IgA deposition at the BMZ, irrespec-
tive of concurrent weak IgG deposition, is consistent with a diagnosis of LABD [211, 212]. 
Moreover, IF staining intensity depends on the experimental conditions, such as dilution and 
the type of second step antibodies. Thus, it is often difficult to assess predominance [116]. 
Several cases of subepidermal blistering diseases including BP, CP and AEB with linear IgA 
deposits reported previously point to the complicated immunopathological features of these 
disease spectrums [213–215].
In minority of the cases, circulating IgG anti-BMZ antibodies can be detected and deposition of 
linear IgG may be seen by DIF parallel to IgA although in less intensity [158]. A Japanese review 
of 213 patients with LABD found both IgA and IgG anti-BMZ antibodies in approximately 
20% of the cases [216]. Therefore, several authors consider them to be overlap syndromes and 
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prefer the designation of linear IgA/IgG bullous dermatosis (LAGBD) [120, 194, 208]. LAGBD 
comprises a heterogeneous group of diseases, and most cases show pruritic vesiculobullous 
eruptions similar to those of LABD [212].
2.9. Treatment
The involvement site and the severity of the disease should be considered for treatment 
choice. Potent topical corticosteroids (clobetasol propionate) may be effective in mild disease 
[217]. The possibility of a drug effect or an association with underlying malignancy or bowel 
disease should be evaluated because discontinuation of the offending drug or treating the 
underlying disease may produce a remission. If there is no evidence of an associated medica-
tion or disease, dapson is the drug of choice for the initial treatment of patients with LABD 
[194]. Many cases often respond dramatically within 24–48 hours to dapsone. It is used in 
doses of 50–200 mg/day. Prednisolone (0.5–2 mg/kg/d) treatment may be added in cases with 
dapson resistance [114]. When there is intolerance to dapson or inadequate response, alterna-
tive treatments with sulfapyridine, colchicine, tetracycline and niacinamide, mycophenolate, 
azathioprine or rituximab should be considered [194]. In case of ocular disease, rituximab is 
indicated in patients with dapson resistance [218]. Cyclophosphamide or other immunosup-
pressants are the next options [194].
In general, same drug regimens can be used for both children and adults, but dose adjustment 
is required in children. Legendre et al. have used botulinum toxin A for LABD located in the 
axillae and observed a decrease in severity of symptoms [219]. Although treatment-discon-
tinuation modalities were not investigated, it is commonly accepted that treatment should 
not be ended before DIF becomes negative in skin with a previously positive lesion site [174].
2.10. Prognosis
The natural course of the disease cannot be estimated precisely because of the rare occurrence 
of LABD and the inadequate long-term follow-up of patients. According to Gottlieb study, it 
is achieved that one-third of patients had complete remission. One-third of the patients had 
chronic disease and the other one-third had relapses. Major risk factors for chronic disease are 
mucosal involvement, age over 70 years and pure linear IgA deposits at the BMZ. Mucosal 
lesions are more resistant to treatment and may lead to stricture formation or conjunctival and 
corneal scarring [174].
The clinical course of CBDC is mild, and mucosal involvement is less common than adult 
form [131]. CBDC is self-limited disease. The average duration of the disease is 3–4 years, but 
it may be longer in some patients.
3. Conclusion
To conclude, AEB and LABD are distinct autoimmune blistering diseases with various sub-
types some of which share overlapping clinical and immunohistopathologic features. No 
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histologic features differentiate LABD from AEB or other subepidermal bullous diseases. 
Immunofluorescence microscopy is mandatory for diagnosis. However, diagnosis and man-
agement of these diseases still remain challenging because of the polymorphous clinical pic-
ture, sophisticated diagnostic approach and lack of prospective controlled clinical trials. Future 
studies are required to clarify the exact role of numerous basal membrane antigens/epitopes, 
border lines between overlapping autoimmune bullous diseases and new therapeutic options.
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